Tomer Adar1, Shimon Shteingart2, Ami Ben-Ya'acov2, Ariella Bar-Gill Shitrit2, Dan M Livovsky2, Shimrit Shmorak2, Mahmud Mahamid2, Bernardo Melamud2, Fiona Vernea3, Eran Goldin2. 1. Digestive Diseases Institute, Shaare Zedek Medical Center, Affiliated with the Hebrew University School of Medicine, 12 Bayit St., 91031, Jerusalem, Israel. adartom@szmc.org.il. 2. Digestive Diseases Institute, Shaare Zedek Medical Center, Affiliated with the Hebrew University School of Medicine, 12 Bayit St., 91031, Jerusalem, Israel. 3. Department of Pathology, Shaare Zedek Medical Center, Jerusalem, Israel.
Abstract
BACKGROUND: Involvement of eotaxin-1 in inflammatory bowel disease has been previously suggested and increased levels of eotaxin-1 have been described in both ulcerative colitis and in Crohn's disease. The association between serum levels of eotaxin-1 and that within the colonic mucosa has not been well defined, as is the potential therapeutic value of targeting eotaxin-1. AIMS: To characterize serum and intestinal wall eotaxin-1 levels in various inflammatory bowel disease patients and to explore the effect of targeting eotaxin-1 by specific antibodies in dextran sodium sulfate-induced colitis model. METHODS: Eotaxin-1 levels were measured in colonic biopsies and in the sera of 60 ulcerative colitis patients, Crohn's disease patients and healthy controls. We also followed in experimental colitis the effect of targeting eotaxin-1 by a monoclonal antibody. RESULTS: Colon eotaxin-1 levels were significantly increased in active but not in quiescent ulcerative colitis and Crohn's disease patients compared to healthy controls. Levels of eotaxin-1 in the colon were correlated with eosinophilia only in tissues from active Crohn's disease patients. Our results did not show any statistically significant change in serum eotaxin-1 levels among ulcerative colitis, Crohn's disease and healthy controls. Moreover, we demonstrate that in dextran sodium sulfate-induced colitis, targeting of eotaxin-1 with 2 injections of anti eotaxin-1 monoclonal antibody ameliorates disease activity along with decreasing colon weight and improving histologic inflammation. CONCLUSION: Eotaxin-1 is increasingly recognized as a major mediator of intestinal inflammation. Our preliminary human and animal results further emphasize the value of targeting eotaxin-1 in inflammatory bowel disease.
BACKGROUND: Involvement of eotaxin-1 in inflammatory bowel disease has been previously suggested and increased levels of eotaxin-1 have been described in both ulcerative colitis and in Crohn's disease. The association between serum levels of eotaxin-1 and that within the colonic mucosa has not been well defined, as is the potential therapeutic value of targeting eotaxin-1. AIMS: To characterize serum and intestinal wall eotaxin-1 levels in various inflammatory bowel diseasepatients and to explore the effect of targeting eotaxin-1 by specific antibodies in dextran sodium sulfate-induced colitis model. METHODS:Eotaxin-1 levels were measured in colonic biopsies and in the sera of 60 ulcerative colitispatients, Crohn's diseasepatients and healthy controls. We also followed in experimental colitis the effect of targeting eotaxin-1 by a monoclonal antibody. RESULTS: Colon eotaxin-1 levels were significantly increased in active but not in quiescent ulcerative colitis and Crohn's diseasepatients compared to healthy controls. Levels of eotaxin-1 in the colon were correlated with eosinophilia only in tissues from active Crohn's diseasepatients. Our results did not show any statistically significant change in serum eotaxin-1 levels among ulcerative colitis, Crohn's disease and healthy controls. Moreover, we demonstrate that in dextran sodium sulfate-induced colitis, targeting of eotaxin-1 with 2 injections of anti eotaxin-1monoclonal antibody ameliorates disease activity along with decreasing colon weight and improving histologic inflammation. CONCLUSION:Eotaxin-1 is increasingly recognized as a major mediator of intestinal inflammation. Our preliminary human and animal results further emphasize the value of targeting eotaxin-1 in inflammatory bowel disease.
Authors: P Manousou; G Kolios; V Valatas; I Drygiannakis; L Bourikas; K Pyrovolaki; I Koutroubakis; H A Papadaki; E Kouroumalis Journal: Clin Exp Immunol Date: 2010-11 Impact factor: 4.330
Authors: S Shteingart; M Rapoport; I Grodzovski; O Sabag; M Lichtenstein; R Eavri; H Lorberboum-Galski Journal: Gut Date: 2008-10-31 Impact factor: 23.059
Authors: Andres J Yarur; Maria T Abreu; Amar R Deshpande; David H Kerman; Daniel A Sussman Journal: World J Gastroenterol Date: 2014-04-07 Impact factor: 5.742
Authors: Claire M Smyth; Nadim Akasheh; Sara Woods; Elaine Kay; Ross K Morgan; Margaret A Thornton; Anthony O'Grady; Robert Cummins; Orla Sheils; Peter Smyth; Gerald J Gleich; Frank M Murray; Richard W Costello Journal: PLoS One Date: 2013-05-22 Impact factor: 3.240
Authors: Lori A Coburn; Sara N Horst; Rupesh Chaturvedi; Caroline T Brown; Margaret M Allaman; Brooks P Scull; Kshipra Singh; M Blanca Piazuelo; Maithili V Chitnavis; Mallary E Hodges; Michael J Rosen; Christopher S Williams; James C Slaughter; Dawn B Beaulieu; David A Schwartz; Keith T Wilson Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240
Authors: Colin J Worby; Henry L Schreiber; Timothy J Straub; Lucas R van Dijk; Ryan A Bronson; Benjamin S Olson; Jerome S Pinkner; Chloe L P Obernuefemann; Vanessa L Muñoz; Alexandra E Paharik; Philippe N Azimzadeh; Bruce J Walker; Christopher A Desjardins; Wen-Chi Chou; Karla Bergeron; Sinéad B Chapman; Aleksandra Klim; Abigail L Manson; Thomas J Hannan; Thomas M Hooton; Andrew L Kau; H Henry Lai; Karen W Dodson; Scott J Hultgren; Ashlee M Earl Journal: Nat Microbiol Date: 2022-05-02 Impact factor: 30.964
Authors: Klas Holmgren; Pär Jonsson; Christina Lundin; Peter Matthiessen; Jörgen Rutegård; Malin Sund; Martin Rutegård Journal: BJS Open Date: 2022-05-02
Authors: Maria Dobre; Elena Milanesi; Teodora Ecaterina Mănuc; Dorel Eugen Arsene; Cristian George Ţieranu; Carlo Maj; Gabriel Becheanu; Mircea Mănuc Journal: J Immunol Res Date: 2018-10-17 Impact factor: 4.818